Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 139,065,000	$ 123,436,000
Short-term marketable securities (amortized cost of $214,115 and $564,036, respectively)	213,996,000	564,833,000
Accounts receivable, net	17,409,000	10,047,000
Inventory	19,263,000	14,063,000
Prepaid expenses and other current assets	13,015,000	14,535,000
Total current assets	402,748,000	726,914,000
Long-term assets
Property and equipment, net	85,262,000	39,692,000
Operating lease right-of-use assets	87,678,000	99,350,000
Long-term marketable securities (amortized cost of $218,163 and $118,429, respectively)	217,145,000	118,525,000
Restricted cash	2,138,000	2,138,000
Intangible assets, net	8,526,000	10,225,000
Goodwill	118,972,000	118,972,000
Other assets	875,000	598,000
Total assets	923,344,000	1,116,414,000
Current liabilities
Accounts payable	3,307,000	3,237,000
Accrued liabilities	9,343,000	13,162,000
Accrued compensation and benefits	15,642,000	11,950,000
Current portion of operating lease liabilities	5,055,000	3,529,000
Current portion of deferred revenue	80,460,000	73,319,000
Total current liabilities	113,807,000	105,197,000
Long-term liabilities
Operating lease liabilities, less current portion	106,685,000	104,333,000
Deferred revenue, less current portion	98,750,000	163,618,000
Total liabilities	319,242,000	373,148,000
Commitments and contingencies (Note 11)
Shareholders’ equity
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020
Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2021 and 2020; 141,393,865 and 137,646,896 shares issued and outstanding at December 31, 2021 and 2020, respectively	14,000	14,000
Additional paid-in capital	1,324,006,000	1,253,971,000
Accumulated other comprehensive (loss) gain	(1,137,000)	893,000
Accumulated deficit	(718,891,000)	(511,612,000)
Total Adaptive Biotechnologies Corporation shareholders’ equity	603,992,000	743,266,000
Noncontrolling interest	110,000
Total shareholders’ equity	604,102,000	743,266,000
Total liabilities and shareholders’ equity	$ 923,344,000	$ 1,116,414,000